Dinapsoline

Drug Profile

Dinapsoline

Alternative Names: DAR 0200A; DAR 200

Latest Information Update: 30 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DarPharma
  • Class Antiparkinsonians; Isoquinolines; Naphthols
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease; Schizophrenia

Most Recent Events

  • 29 Jun 2004 Dinapsoline is available for licensing (http://www.darpharma.com)
  • 29 Jun 2004 Preclinical trials in Schizophrenia in USA (PO)
  • 26 Apr 2001 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top